Assessing the efficacy of darolutamide in metastatic hormone-sensitive prostate cancer based on subgroup meta-analysis and reconstructed individual patient data

Abstract Background Recently published phase III clinical trials documented that darolutamide could improve the prognosis of patients with metastatic hormone-sensitive prostate cancer (mHSPC). This meta-analysis aims to assess the efficacy of darolutamide in mHSPC based on subgroups and reconstructe...

詳細記述

書誌詳細

主要な著者:	Fuxun Zhang, Zhirong Luo, Qi Xue, Xuyan Guo, Qiang Fu, Wei Zhang, Yang Xiong, Pati-Alam Alisha, Uzoamaka Adaobi Okoli, Geng Zhang, Yong Jiao
フォーマット:	Artigo
言語:	Inglês
出版事項:	Springer 2025-11-01
シリーズ:	Discover Oncology
主題:	Prostate cancer Androgen deprivation therapy Darolutamide Prognosis Outcome.
オンライン･アクセス:	https://doi.org/10.1007/s12672-025-03875-4
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!